Summary: Maraviroc is the first CCR5 coreceptor antagonist to receive marketing approval from the Food and Drug Administration (FDA) for the treatment of CCR5-tropic human immunodeficiency virus ...
The chemokine receptors CCR5 and CXCR4 are the two major coreceptors for HIV entry. Numerous efforts have been made to develop a new class of anti-HIV agents that target these coreceptors as an ...
Today, shares of CytoDyn Inc. (OTCQB: CYDY) are on a tear as the biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, announced ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback